These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32161955)

  • 1. Hepatitis C and Stimulant Use Disorder: Challenges and Opportunities.
    Bach P; Ti L
    Clin Infect Dis; 2020 Dec; 71(11):3009. PubMed ID: 32161955
    [No Abstract]   [Full Text] [Related]  

  • 2. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!
    Springer SA; Del Rio C
    Clin Infect Dis; 2020 Oct; 71(7):1723-1725. PubMed ID: 32011653
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug and Alcohol Dependence response to KK-21-1460 "Considering rationales for use in defining subgroups for the treatment of stimulant use disorder".
    Chan B; Freeman M; Ayers C; Korthuis P; Paynter R; Kondo K; Kansagara D
    Drug Alcohol Depend; 2021 Apr; 221():108571. PubMed ID: 33597113
    [No Abstract]   [Full Text] [Related]  

  • 4. To Eliminate Hepatitis C in People Who Inject Drugs, Stop Ignoring Drug-user Health.
    Kattakuzhy S; Rosenthal E
    Clin Infect Dis; 2021 Jul; 73(1):e119-e121. PubMed ID: 32445562
    [No Abstract]   [Full Text] [Related]  

  • 5. News Brief: Hepatitis C cases among pregnant women increased dramatically since the U.S. opioid epidemic began.
    Am J Nurs; 2023 Nov; 123(11):16. PubMed ID: 37882392
    [No Abstract]   [Full Text] [Related]  

  • 6. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
    Rosenthal ES; Silk R; Mathur P; Gross C; Eyasu R; Nussdorf L; Hill K; Brokus C; D'Amore A; Sidique N; Bijole P; Jones M; Kier R; McCullough D; Sternberg D; Stafford K; Sun J; Masur H; Kottilil S; Kattakuzhy S
    Clin Infect Dis; 2020 Oct; 71(7):1715-1722. PubMed ID: 32009165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulant medication for ADHD in opioid maintenance treatment.
    Abel KF; Bramness JG; Martinsen EW
    J Dual Diagn; 2014; 10(1):32-8. PubMed ID: 25392060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs.
    Von den Hoff DW; Berden FAC; Schellekens AFA
    United European Gastroenterol J; 2021 Dec; 9(10):1101-1102. PubMed ID: 34687156
    [No Abstract]   [Full Text] [Related]  

  • 9. Abuse-Deterrent OxyContin And Hepatitis C.
    Bigal ME
    Health Aff (Millwood); 2019 Apr; 38(4):696. PubMed ID: 30933601
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.
    Shulman M; Greiner M; Bisaga A
    Addiction; 2024 Jan; 119(1):158-159. PubMed ID: 37853655
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C Cascade of Care Among Pregnant Women on Opioid Agonist Pharmacotherapy Attending a Comprehensive Prenatal Program.
    Page K; Leeman L; Bishop S; Cano S; Bakhireva LN
    Matern Child Health J; 2017 Sep; 21(9):1778-1783. PubMed ID: 28699096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Elimination Requires More Than Good Drugs.
    Falade-Nwulia O
    Clin Infect Dis; 2020 Aug; 71(5):1269-1270. PubMed ID: 31563937
    [No Abstract]   [Full Text] [Related]  

  • 13. Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.
    Dore GJ; Valerio H; Grebely J
    Liver Int; 2020 Oct; 40(10):2353-2355. PubMed ID: 33021345
    [No Abstract]   [Full Text] [Related]  

  • 14. Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.
    Murphy SM; Dweik D; McPherson S; Roll JM
    Am J Drug Alcohol Abuse; 2015 Jan; 41(1):88-92. PubMed ID: 25490610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding concurrent stimulant use among people on methadone: A qualitative study.
    McNeil R; Puri N; Boyd J; Mayer S; Hayashi K; Small W
    Drug Alcohol Rev; 2020 Mar; 39(3):209-215. PubMed ID: 32202009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interactions with direct-acting antivirals - less is more.
    Wong GL
    Clin Mol Hepatol; 2021 Jan; 27(1):81-82. PubMed ID: 33317241
    [No Abstract]   [Full Text] [Related]  

  • 17. The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation.
    Gonzalez SA; Trotter JF
    Hepatology; 2018 Apr; 67(4):1600-1608. PubMed ID: 29023920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.
    Verdejo-García A; López-Torrecillas F; Giménez CO; Pérez-García M
    Neuropsychol Rev; 2004 Mar; 14(1):1-41. PubMed ID: 15260137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C among former athletes: association with the use of injectable stimulants in the past.
    Passos AD; Figueiredo JF; Martinelli Ade L; Villanova M; Nascimento MM; Secaf M
    Mem Inst Oswaldo Cruz; 2008 Dec; 103(8):809-12. PubMed ID: 19148421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths.
    Barocas JA; Wang J; Marshall BDL; LaRochelle MR; Bettano A; Bernson D; Beckwith CG; Linas BP; Walley AY
    Drug Alcohol Depend; 2019 Jul; 200():59-63. PubMed ID: 31100636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.